142 related articles for article (PubMed ID: 9688527)
1. Apolipoprotein A-I induced amyloidosis.
Genschel J; Haas R; Pröpsting MJ; Schmidt HH
FEBS Lett; 1998 Jul; 430(3):145-9. PubMed ID: 9688527
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels.
Del Giudice R; Domingo-Espín J; Iacobucci I; Nilsson O; Monti M; Monti DM; Lagerstedt JO
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3038-3048. PubMed ID: 28887204
[TBL] [Abstract][Full Text] [Related]
3. Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis.
Das M; Mei X; Jayaraman S; Atkinson D; Gursky O
FEBS J; 2014 Jun; 281(11):2525-42. PubMed ID: 24702826
[TBL] [Abstract][Full Text] [Related]
4. Chameleon 'aggregation-prone' segments of apoA-I: A model of amyloid fibrils formed in apoA-I amyloidosis.
Louros NN; Tsiolaki PL; Griffin MD; Howlett GJ; Hamodrakas SJ; Iconomidou VA
Int J Biol Macromol; 2015 Aug; 79():711-8. PubMed ID: 26049118
[TBL] [Abstract][Full Text] [Related]
5. The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment.
Gursky O; Mei X; Atkinson D
Biochemistry; 2012 Jan; 51(1):10-8. PubMed ID: 22229410
[TBL] [Abstract][Full Text] [Related]
6. Identification of an amyloid fibril forming peptide comprising residues 46-59 of apolipoprotein A-I.
Wong YQ; Binger KJ; Howlett GJ; Griffin MD
FEBS Lett; 2012 Jun; 586(13):1754-8. PubMed ID: 22609356
[TBL] [Abstract][Full Text] [Related]
7. Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?
Das M; Wilson CJ; Mei X; Wales TE; Engen JR; Gursky O
J Mol Biol; 2016 Jan; 428(2 Pt B):449-62. PubMed ID: 26562506
[TBL] [Abstract][Full Text] [Related]
8. Mutation mapping of apolipoprotein A-I structure assisted with the putative cholesterol recognition regions.
Dergunov AD
Biochim Biophys Acta; 2013 Oct; 1834(10):2030-5. PubMed ID: 23806608
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of aggregation and fibril formation of the amyloidogenic N-terminal fragment of apolipoprotein A-I.
Mizuguchi C; Nakagawa M; Namba N; Sakai M; Kurimitsu N; Suzuki A; Fujita K; Horiuchi S; Baba T; Ohgita T; Nishitsuji K; Saito H
J Biol Chem; 2019 Sep; 294(36):13515-13524. PubMed ID: 31341020
[TBL] [Abstract][Full Text] [Related]
10. Molecular Insights into Human Hereditary Apolipoprotein A-I Amyloidosis Caused by the Glu34Lys Mutation.
Morgado I; Panahi A; Burwash AG; Das M; Straub JE; Gursky O
Biochemistry; 2018 Oct; 57(39):5738-5747. PubMed ID: 30184436
[TBL] [Abstract][Full Text] [Related]
11. The polyphenol (-)-epigallocatechin-3-gallate prevents apoA-IIowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity.
Nakajima H; Nishitsuji K; Kawashima H; Kuwabara K; Mikawa S; Uchimura K; Akaji K; Kashiwada Y; Kobayashi N; Saito H; Sakashita N
Amyloid; 2016; 23(1):17-25. PubMed ID: 26701221
[TBL] [Abstract][Full Text] [Related]
12. Heparin promotes fibril formation by the N-terminal fragment of amyloidogenic apolipoprotein A-I.
Mikawa S; Mizuguchi C; Nishitsuji K; Baba T; Shigenaga A; Shimanouchi T; Sakashita N; Otaka A; Akaji K; Saito H
FEBS Lett; 2016 Oct; 590(20):3492-3500. PubMed ID: 27654470
[TBL] [Abstract][Full Text] [Related]
13. Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes.
Mizuguchi C; Ogata F; Mikawa S; Tsuji K; Baba T; Shigenaga A; Shimanouchi T; Okuhira K; Otaka A; Saito H
J Biol Chem; 2015 Aug; 290(34):20947-20959. PubMed ID: 26175149
[TBL] [Abstract][Full Text] [Related]
14. Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant.
Dalla-Riva J; Lagerstedt JO; Petrlova J
PLoS One; 2015; 10(11):e0143915. PubMed ID: 26605794
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E and apolipoprotein A-1 knock-out mice readily develop amyloid A protein amyloidosis.
Elliott-Bryant R; Cathcart ES
Clin Immunol Immunopathol; 1997 Oct; 85(1):104-8. PubMed ID: 9325076
[TBL] [Abstract][Full Text] [Related]
16. Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity.
Ramella NA; Schinella GR; Ferreira ST; Prieto ED; Vela ME; Ríos JL; Tricerri MA; Rimoldi OJ
PLoS One; 2012; 7(8):e43755. PubMed ID: 22952757
[TBL] [Abstract][Full Text] [Related]
17. Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.
Mei X; Atkinson D
Arch Med Res; 2015 Jul; 46(5):351-60. PubMed ID: 26048453
[TBL] [Abstract][Full Text] [Related]
18. The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils.
Adachi E; Kosaka A; Tsuji K; Mizuguchi C; Kawashima H; Shigenaga A; Nagao K; Akaji K; Otaka A; Saito H
FEBS Lett; 2014 Jan; 588(3):389-94. PubMed ID: 24316228
[TBL] [Abstract][Full Text] [Related]
19. Insights into the interaction of the N-terminal amyloidogenic polypeptide of ApoA-I with model cellular membranes.
Rusciano G; Pesce G; Zito G; Sasso A; Gaglione R; Del Giudice R; Piccoli R; Monti DM; Arciello A
Biochim Biophys Acta; 2016 Apr; 1860(4):795-801. PubMed ID: 26820473
[TBL] [Abstract][Full Text] [Related]
20. Iowa Mutant Apolipoprotein A-I (ApoA-IIowa) Fibrils Target Lysosomes.
Kameyama H; Nakajima H; Nishitsuji K; Mikawa S; Uchimura K; Kobayashi N; Okuhira K; Saito H; Sakashita N
Sci Rep; 2016 Jul; 6():30391. PubMed ID: 27464946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
